Unity Biotechnology (UBX) Faces Nasdaq Delisting under Form 25

Rhea-AI Filing Summary

Unity Biotechnology, Inc. (UBX) filed a Form 25 indicating that the Nasdaq Stock Market LLC will remove UBX common stock from listing and registration under Section 12(b) of the Exchange Act. Nasdaq’s 2025-08-06 submission certifies compliance with Rule 12d2-2 requirements for delisting; the filing references both Exchange-initiated 12d2-2(b) and Issuer-initiated 12d2-2(c) pathways but does not specify which box is checked. No financial metrics, earnings data, or major transactions accompany the notice. Once effective (generally after 10 calendar days), UBX shares will no longer trade on Nasdaq, shifting to over-the-counter markets unless another listing venue is secured.

Insights

Securities Analyst

TL;DR: Nasdaq’s Form 25 delists UBX, removing exchange liquidity and heightening risk for current shareholders.

This filing is materially negative for investors. Exchange removal usually triggers reduced trading volume, wider bid-ask spreads and potential index removals. While Form 25 alone does not disclose the cause (compliance failure or voluntary withdrawal), it confirms that procedural hurdles are cleared and delisting is imminent. The lack of accompanying financial details gives no counterbalancing positives. Holders should monitor where UBX will trade next and assess custodial limitations on OTC securities.

Risk Analyst

TL;DR: Delisting elevates liquidity, settlement, and reputational risks for UBX.

Once Nasdaq trading ceases, institutional ownership may be forced to exit due to mandate restrictions, amplifying price volatility. OTC venues typically have less stringent disclosure and lower analyst coverage, increasing information asymmetry. The filing’s brevity offers no remediation timeline or alternative listing plan, suggesting uncertainty around corporate governance or capitalization standards that triggered the action.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38470

Issuer:	Unity Biotechnology, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3280 Bayshore Boulevard
	Brisbane	CALIFORNIA	94005
Telephone number:					650-689-3196

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-08-06	By	Aravind Menon		Hearings Advisor
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Why is Unity Biotechnology (UBX) being delisted from Nasdaq?

Nasdaq filed Form 25 to remove UBX common stock under Section 12(b); the filing does not specify the underlying compliance or voluntary reason.

When will the UBX delisting take effect?

Form 25 becomes effective generally 10 days after filing, making the delisting effective on or about 2025-08-16.

Will UBX shares still trade after delisting?

Yes, they typically transition to over-the-counter markets, though liquidity and coverage often decline.

Does the Form 25 include any financial results for UBX?

No. The document is procedural and contains no revenue, earnings, or balance-sheet data.

What rules govern this delisting action?

Nasdaq cites compliance with 17 CFR 240.12d2-2(b) and 12d2-2(c), covering exchange- and issuer-initiated removals.